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a  b  s  t  r  a  c  t
Objective: To describe the clinical manifestations and outcome of acute liver failure (ALF)
associated  with dengue viral infection, a rare but severe complication.
Methods:  One hundred and ﬁfty ﬁve consecutive patients with ALF admitted to the national
liver  centre from 2001 to 2009 were reviewed retrospectively. Eight cases due to dengue
infection  were identiﬁed and their clinical characteristics are described.
Results:  All patients had severe dengue with one dengue shock syndrome. The median (min-
imum, maximum) age was 33.5 (17, 47) years with 50% female. The median (minimum,
maximum)  duration from the onset of fever to development of ALF was 7.5 (5, 13) days and
the  maximum hepatic encephalopathy (HE) grade were III in ﬁve patients and II in three
patients.  Three patients had systemic inﬂammatory responses (SIRS) on admission and
were  in grade III HE. The presence of SIRS on admission was associated with higher grade of
HE and its development during the course of hospitalization was associated with worsening
HE  grade. The hepatitis was characterized by marked elevations in: alanine transaminase
[median  admission 1140.5 u/L (639, 4161); median peak 2487 u/L (998, 5181)], serum bilirubin
[median  admission 29 mol/L (23, 291); median peak 127 mol/L (72, 592)], and prothrombin
time  [median admission 16.8 s (15.3, 26.2); median peak 22 s (15.3, 40.7)]. The survival rate
with  standard medical therapy alone was 100%.Conclusions: Dengue associated ALF manifest about one week after the onset of fever with
severe  hepatitis and encephalopathy. In our experience, the outcome with standard medical
therapy  alone is excellent.
million  dengue infections occur annually. In the last 50 years,
13 EIntroduction
Dengue is caused by a small, 50 nm diameter single stranded
© 20RNA  virus of the genus Flavivirus, family Flaviviridae. There
are  four distinct serotypes called dengue virus type 1 to 4 or
DEN-1  to DEN-4. The dengue virus is transmitted to humans
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Este é um artigo Open Access sob a licençthrough the bites of infected Aedes mosquitoes mainly the
female  Aedes aegypti.1
The World Health Organization (WHO) estimated that 50
lsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDpital, Lebuhraya Selayang-Kepong 68100 Batu Caves, Selangor,
the  incidence has increased by 30 folds with the expansion of
geographical  distribution to about 100 countries and to the
rural  areas making it the most rapidly spreading arboviral
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nfection.2 This phenomenon is thought to be contributed by
he  worldwide expansion of trade and travel which increased
he  spread of mosquitoes as well as rapid urbanization which
ncreased  mosquitoes breeding sites.2
Dengue infection may  present as self-limiting acute febrile
llness  or the more  severe forms with dengue shock syndrome,
leeding  and other major organ involvements. Gastroin-
estinal manifestations like hepatitis, acute liver failure,
calculous cholecystitis, acute pancreatitis, acute parotitis
nd  diarrhoea have also been reported.3 Hepatitis is common
nd  can be found in 60–90% of dengue infected patients.4–6
ortunately, the transaminitis is usually mild to moderate and
evere  hepatitis with transaminases above ten times the upper
imits  of normal is less common at 3–11%.5,6
Acute liver failure (ALF) associated with dengue fever has
een  described, with most reports occurring among children
nd  a few individual case reports in adults.7–14 In the studies
nvolving children, fatal outcomes and a mortality rate of 50%
ad  been reported.15 Although most of the cases reported were
rom  the tropics, one case occurred in a returned international
raveller.14
The pathogenesis of dengue associated liver injury is not
ully  understood but thought to be due to a direct viral effect or
rom a dysregulated immune response. Histological ﬁndings of
epatocytes  necrosis at zone two and councilman bodies had
een  reported.16 Other potential causes of hepatitis in dengue
atients  are ischaemic or hypoxic liver injury due to circu-
atory  compromise and also drug induced liver injury since
edications like acetaminophen or herbal remedies are usu-
lly  taken for the commonly associated symptoms of fever and
ody  aches.
The  aim of this study was  to describe in details the clin-
cal  characteristics and outcome of a series of adult dengue
atients  with acute liver failure, a hepatology emergency
hich is no longer restricted to the tropics due to the increas-
ng  travel and trade.
aterials  and  methods
atients
rom 2001 to 2009, all ALF cases above the age of 12 years who
ere  referred to the national liver centre were analyzed. The
riteria  for diagnosis of ALF were the presence of encephalo-
athy and coagulopathy (PT > 15 s) within 26 weeks of the ﬁrst
ymptoms  without previous underlying liver disease.17
Among the 155 ALF cases, eight were diagnosed to have
engue fever. The diagnosis of dengue fever was  based on
ompatible  clinical and laboratory conditions (positive anti-
engue  IgM antibody and acute febrile illness with two or
ore  of the following: headache, retro-orbital pain, myalgia,
rthralgia, rash, haemorrhagic manisfestations, haemocon-
entration, low platelet counts).
The severity of the dengue infection was  also classiﬁed
ccording to the WHO  2009 classiﬁcations: (a) dengue with-
ut  warning signs, (b) dengue with warning signs or (c) severe
engue  which is deﬁned by one or more  of the following fea-
ures:  (i) plasma leakage with shock (dengue shock) and/or3;1  7(2):164–169  165
ﬂuid  accumulation with respiratory distress, and/or (ii) severe
bleeding,  and/or (iii) severe organ impairment.2
Clinical  assessments
Consist of detailed history taking (collateral history and refer-
ral  notes were used in patients who were encephalopathic)
and full physical examinations with attention to pupilary size
and  response as well as neurological examinations of the
lower  limbs for tone, reﬂexes, clonus and plantar responses.
Hepatic encephalopathy (HE) was  graded according to the
West  Haven Criteria. The components of systemic inﬂam-
matory  response (temperatures > 38 ◦C or <36 ◦C, white blood
count  > 12,000 or <4000/mm3, pulse rate > 90 beats/min, respi-
ratory  rates > 20 breaths/min or PaCO2 < 4.3 kPa) were  assessed
on  admission and at the onset of worsening encephalopathy.
Laboratory  and  radiological  tests
Dengue serology was done using PANBIO Dengue
Immunoglobulin M Capture ELISA. Other laboratory tests
carried  out were full blood counts, liver function tests, renal
proﬁle,  coagulation proﬁle, Hepatitis B surface antigen,
anti-Hepatitis C antibody and IgM anti-Hepatitis A antibody.
Acetaminophen levels were assayed when indicated. Cultures
of  blood, sputum or tracheal aspirates and urine were  carried
out  once weekly and when clinically indicated. Radiologi-
cal  examinations were transabdominal ultrasonography in
all patients and non-contrast CT scan of the brain when
indicated.
Ethical  approval
Since this study was a case series and retrospective in nature,
there  are no consent taken from the patients and we received
approval  from Medical Review and Ethics Committee (MREC)
of  the Ministry of Health Malaysia.
Data  analysis
As this study involved small data sets and the distribution is
skewed,  the continuous variables were  presented in medians
with  minimum and maximum values while the categorical
data  were presented in total number and/or percentages.
Results
Demographics  and  clinical  features  at  admission
During the study period from 2001 to 2009, eight out of 155
adults  (5.2%) with ALF were diagnosed to have dengue fever.
The  median (minimum, maximum) age was  33.5 (17, 47) years
with  50% female. All the patients had features of severe
dengue with one case in dengue shock according to the WHO
2009  classiﬁcations.Four  out of the six patients who could give history, com-
plained of right upper quadrant pain and in one of them,
there  was  clinical and ultrasound evidence of hepatomegaly.
One of the remaining two patients who could not provide
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coherent history also had hepatomegaly. In both cases with
hepatomegaly, the liver spans were 16.1 cm by ultrasound
measurement.
On  admission, three patients were in grade III HE while
two  were in grade II and three did not have HE. All the three
patients  who were  in grade III HE had more  than one sys-
temic  inﬂammatory response (SIRS) on admission. The three
patients  without SIRS criterion were not encephalopathic and
the  remaining two patients with grade II HE had only one SIRS
criterion.
All  the patients were  tested negative for Hepatitis B surface
antigen,  anti-Hepatitis C antibody and IgM anti-Hepatitis A
antibody.  The median (minimum, maximum) acetaminophen
levels of the ﬁve patients who had taken acetaminophen dur-
ing  the illness were  9.8 (<6.6, 64.4) mol/L. However these
patients did not have the poor prognostic King’s College
Criteria for acetaminophen overdose when they developed
encephalopathy. The other laboratory results at the time of
admission  are in Table 1.
Clinical  course  and  progress  in  hospital
One of the three non-encephalopathic patients progressed to
grade II HE on day four of admission and two deteriorated to
grade  III HE on day two and four respectively. All of them had
more  than one SIRS criterion when the grade of HE worsened,
while  the two grade II HE patients who did not progress into
higher  grades of HE, did not develop SIRS.
Therefore the maximum grade of HE was  grade III in ﬁve
patients  and grade II in three patients, all occurring within
one  to four days of admission to our hospital. The median
(minimum, maximum) duration from the onset of fever to the
development  of HE or ALF was  7.5 (5, 13) days. All the ﬁve
grade  III HE patients were  electively intubated for cerebral pro-
tection.  Lower limbs hyperreﬂexia and sustained clonus were
found  in three patients and one had bilateral upgoing plan-
tars  response. Pupilary abnormality was  documented in one
patient  only. Non-contrast CT scan of the brain was  carried
out  in four of them and the ﬁndings were normal.
During the course of the illness, one patient developed
ascites and pleural effusion, two patients had ascites alone
and  another two had pleural effusions alone. One male patient
aged  38 with peak values for alanine transaminase (ALT)
1169  u/L, aspartate transaminase (AST) 2608 u/L, prothrombin
time  of 38 s and grade II HE developed melena. An emergency
upper  endoscopy revealed altered blood with mucosal slough-
ing  in the stomach.
Six  patients (75%) acquired culture proven infections and
the  sites of positive cultures were respiratory (n = 4), blood
(n  = 3) and urine (n = 2). All these patients had presence of SIRS.
The  remaining two patients who  never had SIRS, did not have
any  positive cultures.
The  peak values of the liver and renal parameters during
the  hospitalization and the duration of time with ALT ≥ 500 u/L
are presented in Table 1.Clinical  managements
All the patients were nursed with the head of bed ele-
vated at 30◦ and enteral nutrition support was  initiated 1 3;1 7(2):164–169
whenever possible. Fluid managements with crystalloids and
colloids  and correction of coagulopathy with fresh frozen
plasma  and platelets were carried out as clinically indicated.
All  but one patient received N-acetylcysteine infusion at
100–150  mg/kg/day for a minimum of ﬁve days. Broad spec-
trum  antibiotics were started on all patients and ﬂuconazole
was  given to six patients. Three patients received mannitol
and  3% saline infusions for clinical signs of raised intracranial
pressure. Only one of the three patients with renal impairment
required renal replacement therapy during the acute illness.
Outcomes  and  follow-up  data
The median (minimum, maximum) duration of intubation in
the ﬁve patients with grade III HE was 11 (2, 17) days. All the
patients  were  discharged well after 13.5 (5, 35) days of hospi-
talization  and the seven patients who were followed up had
normalization of ALT with a median value of 24 u/L (14, 38).
Discussion
In this series of eight patients, we found that adult dengue
patients who developed acute liver failure did so at a median
of  7.5 days (5, 13) after the onset of fever with some occur-
ring  in the recovery phase of dengue illness. According to
the  WHO  2009 classiﬁcations, all our patients had features
of  severe dengue infection. These ﬁndings are comparable to
other case reports which reported ALF at ﬁve to 14 days from
the  onset of fever and associated with severe types of dengue
infections.10–13
Interestingly similar to acute liver failures of other aetiolo-
gies,  we found that the presence of SIRS in dengue related
ALF  is also associated with higher grade of hepatic ence-
phalopathy, with worsening of encephalopathy and positive
microbiology.18
After a period of three to seven days incubation, the course
of  dengue illness typically starts with an acute febrile phase
for  two to seven days. This is followed by a critical phase
at  around the time of defervescence starting from three to
seven  days of the illness during which there are increased
capillary permeability and systemic vascular leak. Those who
survived  through the 24–48 h of clinically signiﬁcant plasma
leakage  in the critical phase will enter the recovery phase with
rapid  improvement in symptoms.2,19 The dengue virus and the
virus-encoded NS1 are present in the blood during the acute
phase  of illness.19 A study by Thomas et al. on two serotypes of
the  dengue virus, DEN-2 and DEN-4, showed that the dengue
viral  load fell from day one to six of illness and more severe
presentation was  associated with higher viral load.20
In our patients, the maximum grade of encephalopathy
occurred on either the same day (n = 6) or one to two days (n = 2)
after  the ALT peaks. These were at ﬁve to 13 days from the
onset  of fever which may  coincide with about one week after
the  viral surge. Therefore, health care providers who are look-
ing  after severe dengue cases with hepatitis should look out
for  early signs of ALF in the recovery phase of dengue illness
at  around or shortly after the time of ALT peaks together with
the  development of SIRS criteria.
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Table 1 – Demographic, clinical and laboratory features of patients at the time of admission and the worst results
according to the maximum hepatic encephalopathy grade.
Grade III (n = 5) Grade III (n = 5) All (n = 8)
Median Min, max Median Min, max Median Min, max
Demographic
Age (years) 36.0  17.0, 38.0 31.0 22.0, 47.0 33.5 17.0, 47.0
Gender
Male  1 3 4
Female 2 2 4
Clinical
Fever to onset of HE (days) 7.0 6.0, 13.0 8.0 5.0, 11.0 7.5 5.0, 13.0
HE grade at admission
No  HE 1 2 3
Grade II 2 0 2
Grade III 0 3 3
SIRS at admission
≤1  3 2 5
>1 0 3 3
Paracetamol intake
Yes  2 3 5
No 1 2 3
Length of stay (days) 10.0 5.0, 12.0 22.0 13.0, 35.0 13.5 5.0, 35.0
Laboratory results (at admission)
ALT  (u/L) 1083.5 998.0, 1169.0 1311.0 847.0, 4161.0 1140.5 639.0, 4161.0
AST  (u/L) 1781.5 955.0, 2608.0 3779.0 1139.0, 14,576.0 2777.0 955.0, 14,576.0
ALP  (u/L) 257.5 161.0, 354.0 241.0 131.0, 300.0 241.0 131.0, 354.0
Serum bilirubin (mol/L) 181.5 72.0, 291.0 67.0 23.0, 78.0 68.0 23.0, 291.0
Serum albumin (g/L) 26.5 24.0, 29.0 30.0 26.0, 35.0 29.0 24.0, 35.0
PT  (s) 19.7 15.3, 24.0 16.8 13.3, 26.2 16.8 13.3, 26.2
APTT (s) 41.3 28.6, 41.3 39.2 34.2, 50.2 39.2 28.6, 50.2
Fibrinogen (mg/dL) 139.5 137.0, 142.0 230.0 161.0, 256.0 228.0 137.0, 256.0
White  cell count (103/L) 8.2 7.6, 29.9 19.9 4.6, 24.6 14.0 4.6, 29.9
Haemoglobin (g/dL) 10.2 10.0, 15.0 12.2 6.6, 16.5 11.5 6.6, 16.5
Platelet count (103/L) 38.0 34.0, 59.0 62.0 5.0, 123.0 48.5 5.0, 123.0
Haematocrit (%) 30.7 29.8, 41.0 35.8 20.0, 46.0 33.4 20.0, 46.0
Serum creatinine (mol/L) 53.0 40.0, 162.0 127.6 86.0, 197.0 107.5 40.0, 197.0
Laboratory results (during inpatient)
Maximum  ALT (u/L) 1169.0 998.0, 1818.0 4089.0 1311.0, 5181.0 2487.0 998.0, 5181.0
Maximum PT (s) 15.3 15.3, 32.6 24.0 18.6, 40.7 22.0 15.3, 40.7
Maximum billirubin (mol/L) 164.0 72.0, 358.0 90.0 82.0, 592.0 127.0 72.0, 592.0
Minimum albumin (g/L) 24.0 17.0, 24.0 18.0 16.0, 20.0 18.5 16.0, 24.0
Number of days ALT ≥ 500 u/L 4.0 3.0, 5.0 6.0 2.0, 9.0 5.5 2.0, 9.0
Maximum creatinine (mol/L) 56.0 51.0, 162.0 116.0 86.0, 543.0 114.0 51.0, 543.0













daspartate transaminase; ALP, alkaline phosphatase; PT, prothrombin 
33.9 s. Gender, HE grade at admission, SIRS at admission and paracet
Our patients had markedly elevated serum transaminases
t values above 10 times the upper limit of normal and the AST
evels  were  higher than ALT as found in the few case reports of
engue  associated ALF.7–14 The AST levels are also higher than
LT  in the other milder form of dengue hepatitis.4,6,21 The AST
ad  been reported to peak at about seven to eight days after
he  onset of illness and the ALT lags behind AST in time and
agnitude.6
We  did not ﬁnd co-infection with hepatitis A, B or C in our
LF  patients. Acute and chronic hepatotrophic viral hepati-
is  are common in this region, and there are valid concern
hat  concomitant infection will results in more  severe liver
isease.  Two older studies reported that hepatitis B or C control, 11.2 s; APTT, activated partial thromboplastin time, control,
 intake were reported in frequency.
co-infection  did not affect the level of transaminitis.4,6 How-
ever,  two recent studies showed signiﬁcantly higher ALT levels
in  dengue patients with chronic hepatitis B compared to those
without.21,22 Luckily, the studies did not ﬁnd any detrimen-
tal effect from the higher transaminases on the coagulation
proﬁle or severity of liver disease.21
Five of our patients developed ascites or pleural effusion
or  both, these were probably due to plasma leakage in the
critical  phase of dengue illness, the low oncotic pressure
and  volume overload. Plasma leakage is a feature of severe
dengue  fever.2 Transient endothelial dysfunction occurs in
dengue  illness and it can cause hypoalbuminemia and
proteinuria.19,23,24
















2168  b r a z j i n f e c t d 
Our patients received N-acetylcysteine infusion as part
of  the medical therapy for ALF without adverse effects.
Kumarasena et al. reported similar experience in dengue
ALF.25 Apart from acting as an antidote to paracetamol poi-
soning,  N-acetylcysteine had been proven to improve systemic
haemodynamics and tissue oxygen delivery in acute liver
failure.26,27 Subsequently randomized double-blind, placebo
controlled study had shown that intravenous N-acetylcysteine
improved transplant free survival and well tolerated in non
acetaminophen ALF when given in early stage.28
In our series of eight adults with dengue associated
acute liver failure, the outcome was  good with 100% spon-
taneous  survival from standard medical therapy alone. This
is  in contrast to studies on children which reported 50–66%
mortality.15,29 One of the reasons for better outcome in adults
may  be due to the generally higher mortality from dengue
infection in children.30,31 The host risk factors for severe
dengue are young age, female gender, high body mass index
and  certain host genetic variants. The viral factors were the
virus  strain, and a secondary dengue infection.19
The limitation of our study is the small number but these
cases  are from the country’s only tertiary liver centre and over
a  study period of nine years. In Malaysia, the incidence of
reported  dengue cases between 2001 and 2008 ranged from
72.2  to 180 per 100,000 population, so dengue associated ALF
is  truly a rare manifestation of dengue fever.32
Since this is a rare condition with global concern, we
hope  a detailed description of the clinical ﬁndings in
this  case series will assist clinicians working in countries
with  heavy burden of dengue as well as those practis-
ing in temperate regions who may  come across an ill
returned traveller with ALF. Being aware of the features
of  dengue associated ALF may  help to diagnose the con-
dition  early. This is important as we found that dengue
associated ALF can occur up to 13 days after the onset of
illness.
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